Agenus Inc. (AGEN) Coverage Begins at Dawson James with Buy Rating

Agenus Inc. (AGEN) has been initiated today with coverage from the research analysts at Dawson James.  Dawson James begins this new coverage of AGEN with an initial price target set at $2 dollars and positions their performance outlook of AGEN as “buy.”  AGEN is down during intraday trading despite opening high this morning.

Agenus conducts business in the Health Care sector, particularly the Biotechnology industry.  Agenus is currently trading below its 50 & 200-day moving averages and 2011 is currently a down year for the company.  Notably, AGEN’s price action has been mostly whipsaw since February.

Agenus Inc. is a company that is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches.  As of January 6, 2011, they changed their name from Antigenics Inc. to Agenus Inc. to more accurately reflect their existing product pipeline.  The company has market capitalization of $105,000,000 and 112,654,000 shares outstanding.  AGEN has a 52-week high of $1.16 with the low being 73 cents.



Latest News

Teva Pharmaceutical Industries  Bond Prices Fall 1.3%
Teva Pharmaceutical Industries Bond Prices Fall 1.3%
Corus Entertainment  Stock Price Up 3.1%
Corus Entertainment Stock Price Up 3.1%
ShopZcoin Hits Market Capitalization of $0.00
ShopZcoin Hits Market Capitalization of $0.00
Ethereum Lite Price Up 11.2% Over Last Week
Ethereum Lite Price Up 11.2% Over Last Week
New Jersey Resources Corp  Expected to Announce Earnings of $1.17 Per Share
New Jersey Resources Corp Expected to Announce Earnings of $1.17 Per Share
DAO.Casino Market Cap Reaches $1.77 Million
DAO.Casino Market Cap Reaches $1.77 Million


© 2006-2019 Ticker Report